Similar articles

• Twice weekly vindesine, a phase II study in lung cancer.

  Postmus PE, Mulder NH, Schipper DL, de Vries EG. Postmus PE, et al. J Cancer Res Clin Oncol. 1987;113(1):99-100. doi: 10.1007/BF00389975. J Cancer Res Clin Oncol. 1987. PMID: 3818785 Free PMC article.
• Phase I study of 21 days continuous infusion with vindesine.

  de Vries EG, Smit EF, Vendrig DE, Holthuis JJ, Mulder NH. de Vries EG, et al. Br J Cancer. 1989 Mar;59(3):471-2. doi: 10.1038/bjc.1989.97. Br J Cancer. 1989. PMID: 2930717 Free PMC article. No abstract available.
• Continuous-infusion vindesine in refractory carcinoma of the cervix: a phase II trial.

  Kavanagh JJ, Saul PB, Gershenson DM, Copeland LJ, Wharton JT. Kavanagh JJ, et al. Cancer Treat Rep. 1985 Nov;69(11):1317-8. Cancer Treat Rep. 1985. PMID: 4092193 No abstract available.
• Establishment of the standard regimen for non-small-cell lung cancer in Japan.

  Masuda N. Masuda N. Oncology (Williston Park). 2001 Jan;15(1 Suppl 1):13-8. Oncology (Williston Park). 2001. PMID: 11221016 Review.
• A randomized study of two vindesine plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer.

  Rosell R, Abad-Esteve A, Moreno I, Barnadas A, Carles J, Fernandez C, Ribelles N, Culubret M. Rosell R, et al. Cancer. 1990 Apr 15;65(8):1692-9. doi: 10.1002/1097-0142(19900415)65:8<1692::aid-cncr2820650805>3.0.co;2-x. Cancer. 1990. PMID: 2156597 Review.